Argenica Therapeutics Ltd
AGN
Company Profile
Business description
Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.
Contact
117 Broadway
Unit 4
NedlandsWA6009
AUST: +61 893293396
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,586.70 | 15.30 | 0.18% |
| CAC 40 | 7,657.65 | 206.79 | -2.63% |
| DAX 40 | 23,488.70 | 510.47 | -2.13% |
| Dow JONES (US) | 41,859.09 | 1.35 | -0.00% |
| FTSE 100 | 8,658.90 | 80.36 | -0.92% |
| HKSE | 23,601.26 | 56.95 | 0.24% |
| NASDAQ | 18,925.73 | 53.09 | 0.28% |
| Nikkei 225 | 37,160.47 | 174.60 | 0.47% |
| NZX 50 Index | 12,596.50 | 65.75 | -0.52% |
| S&P 500 | 5,842.01 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,360.90 | 12.20 | 0.15% |
| SSE Composite Index | 3,348.37 | 31.82 | -0.94% |